Sponsored · Video
Nimble Therapeutics Greatly Accelerates Development of Peptide-Based Therapeutics
Jigar Patel, CEO of Nimble Therapeutics, speaks at BIO-Europe® 2019 in Hamburg about the spin-out last April of Nimble from Roche to accelerate the development and discovery of peptide-based therapeutics, and make this technology available to other pharma companies. He sees huge promise in these therapeutics being used in previously undruggable targets that cannot be accessed by small molecules and antibodies. Nimble’s speed in development and chemical diversity differentiates the company from others working on the same problems.